Ascendis Pharma A/S (ASND) Projected to Post Quarterly Earnings on Wednesday

Ascendis Pharma A/S (NASDAQ:ASND) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 5th. Analysts expect the company to announce earnings of ($1.31) per share and revenue of $117.11 million for the quarter.

Ascendis Pharma A/S Trading Down 4.3 %

NASDAQ:ASND opened at $125.09 on Tuesday. The firm has a fifty day simple moving average of $133.51 and a two-hundred day simple moving average of $132.77. Ascendis Pharma A/S has a 12 month low of $111.09 and a 12 month high of $161.00. The stock has a market capitalization of $7.59 billion, a price-to-earnings ratio of -15.48 and a beta of 0.64.

Analysts Set New Price Targets

Several research firms have recently weighed in on ASND. TD Cowen reduced their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research note on Friday, November 15th. JPMorgan Chase & Co. boosted their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Stifel Nicolaus upped their price target on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a report on Friday, November 15th. Finally, Oppenheimer reduced their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating on the stock in a research report on Friday, November 15th. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $191.57.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.